Evaxion Biotech A/S

Equities

EVAX

US29970R2040

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-31 pm EDT			5-day change	1st Jan Change
3.67 ^USD	+1.96%		-9.16%	-46.48%

May. 29	European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Wednesday Trading	MT
May. 28	Earnings Flash (EVAX) EVAXION BIOTECH Reports Q1 Revenue $51,000	MT

BioStock: Evaxion to develop novel precision cancer vaccine concept

January 31, 2024 at 03:19 am EST

Evaxion Biotech has announced an expanded commitment to developing precision cancer vaccines by targeting a novel category of tumour antigens called endogenous retroviruses (ERVs). These will be identified with the company's proprietary target discovery AI-Immunology platform, and proof-of-concept data is expected later this year.

Read the article at biostock.se:

Evaxion to develop novel precision cancer vaccine concept - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

https://news.cision.com/evaxion-biotech/r/biostock--evaxion-to-develop-novel-precision-cancer-vaccine-concept,c3919743

Latest news about Evaxion Biotech A/S

European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Wednesday Trading	May. 29	MT
Earnings Flash (EVAX) EVAXION BIOTECH Reports Q1 Revenue $51,000	May. 28	MT
Evaxion Biotech A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 28	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher Friday, End Week Marginally Lower	May. 24	MT
Evaxion Biotech Plans to Unveil 'Positive' Data From Phase 2 Study of Advanced Melanoma Combination Treatment	May. 24	MT
Evaxion Biotech A/S to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024	May. 23	CI
Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	May. 23	MT
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	May. 22	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading	May. 21	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading	May. 15	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher	May. 13	MT
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	May. 06	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower	May. 03	MT
European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading	May. 02	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading	May. 01	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading	Apr. 29	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	Apr. 26	MT
Evaxion Biotech A/S Elects Lars Staal Wegner as A New Board Member	Apr. 25	CI
Evaxion Announces Phase 2 Clinical Trial Update	Apr. 17	CI
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	Apr. 11	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	Apr. 09	MT
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	Apr. 08	MT
Certain Warrants of Evaxion Biotech A/S are subject to a Lock-Up Agreement Ending on 7-APR-2024.	Apr. 06	CI
Certain American Depositary Shares of Evaxion Biotech A/S are subject to a Lock-Up Agreement Ending on 7-APR-2024.	Apr. 06	CI
Certain Ordinary Shares of Evaxion Biotech A/S are subject to a Lock-Up Agreement Ending on 7-APR-2024.	Apr. 06	CI

Chart Evaxion Biotech A/S

Duration

Period

More charts

Company Profile

Evaxion Biotech A/S is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

Sector

Biotechnology & Medical Research

Calendar

02:30pm - American Society of Clinical Oncology Meeting - Abstract No 9561

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.67 USD

Average target price

11.75 USD

Spread / Average Target

+220.16%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EVAXION BIOTECH A/S	-46.48%	19.48M
MODERNA, INC.	+43.36%	58.06B
IQVIA HOLDINGS INC.	-5.31%	40.53B
LONZA GROUP AG	+37.52%	38.99B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.7B
CELLTRION, INC.	-12.56%	26.56B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.98B
BIO-TECHNE CORPORATION	+0.04%	12.17B
UNITED THERAPEUTICS CORPORATION	+25.12%	12B
MEDPACE HOLDINGS, INC.	+26.04%	11.92B

Other Biotechnology & Medical Research